Document:

EX-10.1

 Exhibit 10.1 
  

 
 Mandate Agreement 

dated as of 27 December 2019 
 by and between 

 
  

					
	CRISPR Therapeutics AG	  	 	(the Company	) 

 Baarerstrasse 14, 6300 Zug, Switzerland 

and 
  

 

					
	Oriolus Consulting LLC	  	 	(the Service Provider	) 

 Husenstrasse 11, 6354 Vitznau, Switzerland 

(the Company and the Service Provider are also referred to as Party or Parties) 

  
 1 of 12 

 Mandate Agreement 

 

  

Preamble 
 The Service Provider offers, among other things,
consulting services in the life sciences sector. 
 The Parties take note that Dr. Rodger Novak (the Advisor) has been acting as the chairman of
the Company’s board of directors (the Chairman and the Company’s board of directors the Board) since his election at the 2018 general meeting of shareholders of the Company. The Advisor has not received any remuneration for
his services as Chairman so far. 
 In addition, the Parties take note that the Advisor acts as the president of the Company (the President) based on
an employment agreement with the Company dated as of 1 December 2017 (the Employment Agreement), replacing the previous employment agreement dated as of 6 October 2016. Based on the previous employment agreement, the Advisor has
been granted a certain number of options (not all of which have vested as of the date hereof) entitling the Advisor to acquire shares of the Company (the Employee Options). 

The Service Provider will cause the Advisor to provide the services related to the Chairman and the President functions (the Services) based on this
mandate agreement (the Agreement) and the Company intends to accept such Services. Consequently, the Employment Agreement shall, except for certain of its provisions, be terminated pursuant to the terms of the termination agreement entered
into by and between the Company and the Advisor as of the date hereof. The Services related to the Chairman and President functions shall from now on be governed by this Agreement. 

Now, therefore, subject to the terms and conditions herein, the Parties agree as follows: 

 
  

	1.	 Description of Services 

 

	1.1.	 General 

The Parties acknowledge and agree that Service Provider shall cause Advisor to perform the Services to the Company and to abide by the terms of this Agreement
by signing Exhibit 1.1. 

  
 2 of 12 

 Mandate Agreement 

 

 The Services shall be performed by the Advisor personally and by no other individual. The Parties confirm
that the Agreement does not constitute an employment relationship between the Advisor and the Company. 
 The Service Provider shall, and shall cause the
Advisor to, safeguard and promote the interests of the Company, procure that the Advisor deploys sufficient time and efforts to perform the contractual duties contemplated by this Agreement and procure that the Advisor exercises the Services
associated with the functions of Chairman and President carefully and with due care and consistent with the terms of this Agreement. 
  

	1.2.	 Chairman Services 

The duties and responsibilities of the Chairman shall include all duties and responsibilities associated with such function as determined by the Board from
time to time as well as those expressly mentioned in the law, particularly the Swiss Code of Obligations, and in this Agreement. 
  

	1.3.	 President Services 

The duties and responsibilities of the President shall include all duties and responsibilities associated with such function as determined by the Board from
time to time. 
  

	1.4.	 Functions on Committees 

If the Advisor performs additional functions in committees of the Board or similar corporate bodies and is compensated for such function, the Service Provider
shall be entitled to receive such compensation. 
  

	1.5.	 Compliance with Laws and Guidelines 

The Service Provider shall procure that the Advisor performs the Services at all times in compliance with applicable law, regulatory requirements (including
any requirements of stock exchanges), the articles of association of the Company, the Company’s organizational regulations, the Company’s code of business conduct and ethics and the Company’s corporate governance guidelines. 

  
 3 of 12 

 Mandate Agreement 

 

  

	2.	 Conflicts of Interest 

The Service Provider procures that the Advisor exercises his function as Chairman and President independently, based on his own professional and diligent
judgment, with due care and in the best interest of the Company. The Service Provider shall avoid and shall procure that the Advisor avoids conflicts of interest and shall promptly inform and procure that the Advisor promptly informs the Board as a
whole if a potential conflict of interest could arise in connection with the performance of the Services. 
  

 

	3.	 Compensation 

  

	3.1.	 Compensation for Chairman Services 

The Service Provider shall not be entitled to any compensation for the Advisor providing the Services in connection with the Chairman function. 

 

	3.2.	 Compensation for President Services 

For each full calendar year, the Service Provider shall be entitled to a compensation of the CHF equivalent to USD 190,000 for the Advisor providing the
Services in connection with the President function, and such amount shall be payable in equal installments on a quarterly basis. 
  

	3.3.	 Additional Compensation; Equity Compensation 

For additional Board functions performed by the Advisor (e.g. formally serving on a committee of the Board), the Service Provider shall be entitled to
additional compensation in accordance with the Company’s Board fee policy and Section 1.4. The Parties acknowledge and agree that, unless the Board expressly determines otherwise, neither Service Provider nor Advisor will be eligible to
receive compensation pursuant to the Company’s Non-Employee Director Compensation Policy, as may be in effect from time to time. 

  
 4 of 12 

 Mandate Agreement 

 

	3.4.	 Compliance with Ordinance against Excessive Compensation 

It is understood and agreed that the compensation set forth in this Section 3 is subject to the approval by the AGM in accordance with the Swiss ordinance
against excessive compensation in listed companies. 
  

	3.5.	 Invoices 

The invoices issued by the Service Provider in accordance with this Section 3 shall be settled within thirty (30) days. The fees set forth in this
Section 3 are exclusive of value-added tax. The value-added tax, if any, is added up and shown additionally on the invoices. 
  

	3.6.	 Options granted to Advisor under Employment Agreement 

The Parties acknowledge that the Advisor has been granted Employee Options as a part of the Advisor’s compensation under the Employment Agreement and the
previous employment agreement replaced by the Employment Agreement. The Employee Options, including those that have not yet vested and the shares of the Company that the Advisor may acquire upon exercise of the Employee Options, have been granted to
the Advisor personally and are not part of the compensation under this Agreement. 
  

 

	4.	 Social Security Insurances 

The Service Provider undertakes that the Advisor be duly insured with the relevant social security insurances (including pension funds), to the extent required
by applicable law. The Company shall be fully indemnified by the Service Provider if it is, for any reason, held liable for social security contributions (including contributions to pension funds) in connection with the Services. 

 
  

	5.	 Expenses 

The Company shall reimburse all expenses reasonably incurred by the Service Provider in connection with the performance of the Services. 

  
 5 of 12 

 Mandate Agreement 

 

  

	6.	 Term 

  

	6.1.	 Entry into Force 

This Agreement enters into force on 1 January 2020. 
  

	6.2.	 Termination 

This Agreement shall continue for an indefinite period of time and may be terminated with respect to the President function by either Party at any time. This
Agreement shall be automatically terminated with respect to both, the Chairman and the President function, on the calendar day on which the Advisor is no longer a member of the Board. In case of termination of the Agreement in accordance with this
Section 6, the Company shall pay the fees to the Service Provider as long as the respective Services have been provided by the Service Provider to the Company (pro rata). 

 
  

	7.	 D&O Insurance 

The Company undertakes to provide a Directors & Officers Liability Insurance Policy covering the Advisor for the Chairman and the President functions
as determined by the Board in its sole discretion. The Service Provider and the Advisor acknowledge that such insurance does not cover all risks and is subject to caps and limitations. 

 
  

	8.	 Non-Compete and
Non-Solicitation, Cooperation and Confidentiality 

  

	8.1.	 Non-Compete and
Non-Solicitation 

 In order to protect the Company’s proprietary information and good
will, during the term of this Agreement and for a period of twelve (12) months following the date of termination (the Restricted Period), the Service Provider will not directly or indirectly, whether as owner, partner, shareholder,
director, manager, consultant, agent, employee, co-venturor or otherwise, engage, participate or invest in any Competing Business. For purposes hereof, the term Competing Business shall mean any entity
engaged in the discovery, development or commercialization of CAS9 technology for human therapeutics. 

  
 6 of 12 

 Mandate Agreement 

 

 Notwithstanding the foregoing, nothing contained hereinabove or hereinbelow shall be deemed to prohibit the
Service Provider from (i) acquiring, solely as an investment, shares of capital stock (or other interests) of any corporation (or other entity) not exceeding two percent (2%) of such corporation’s (or other entity’s) then outstanding
shares of capital stock (or equity interest), or (ii) working for a line of business, division or unit of a larger entity that competes with the Company as long as the Service Provider’s activities for such line of business, division or
unit do not involve work by the Service Provider on matters that are directly competitive with the Company’s business. 
 In addition, during the
Restricted Period, the Service Provider will not, directly or indirectly, in any manner, other than for the benefit of the Company (i) divert or take away customers of the Company or any of its suppliers; and/or (ii) solicit, entice,
attempt to persuade any other employee or consultant of the Company to leave the Company for any reason (other than the termination of subordinate employees undertaken in the course of the employment with the Company). 

The Service Provider acknowledges and agrees that if the Service Provider violates any of the provisions of this Section 8, (i) the running of the
Restricted Period will be extended by the time during which the Service Provider engages in such violation(s), but in no event for a period exceeding three (3) years following the end of the term of this Agreement and (ii) the Service
Provider must provide compensation for the damage incurred by the Company, if any, resulting from the violation of the provisions of this Section 8. 
  

	8.2.	 Litigation and Regulatory Cooperation 

During and after the term of this Agreement, the Service Provider shall use reasonable efforts to cooperate with the Company in the defense or prosecution of
any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while the Service Provider provided Services to the Company. The Service
Provider’s cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually
convenient times. During and after the term of this Agreement, the Service Provider shall use reasonable efforts to cooperate with the Company in connection with any investigation or review of any U.S. federal, state or local regulatory authority as
any such investigation or review relates to events or occurrences that transpired while the Service Provider provided Services to the Company. The Company shall reimburse the Service Provider for any reasonable out-of-pocket expenses incurred in connection with the Service Provider’s performance of obligations pursuant to this Section 8.2.

  
 7 of 12 

 Mandate Agreement 

 

	8.3.	 Confidentiality 

Unless the confidentiality obligations are governed by a separate confidentiality agreement, the confidentiality obligations stated in the second paragraph of
this Section 8.3 shall apply. 
 The Service Provider will have access to confidential and proprietary information relating to the business and
operations of the Company, its group companies and their clients. Such confidential and proprietary information constitutes a unique and valuable asset of the Company and/or other companies of the group and their acquisition required great time and
expense. The disclosure or any other use of such confidential or proprietary information, other than for the sole benefit of the Company or the respective group company, would be wrongful and would cause irreparable harm to the Company. The Service
Provider is under a strict duty to keep all confidential and proprietary information strictly and permanently confidential and, accordingly, shall not during the term of this Agreement or after termination of the Agreement directly or indirectly for
any purpose other than for the sole benefit of the Company or another group company, or disclose or permit to be disclosed to any third person or entity, any confidential or proprietary information without first obtaining the written consent of the
responsible executive and the party concerned, if applicable, except if required to do so by law. 
  

	8.4.	 Protected Reporting; Defend Trade Secrets Act Immunity 

Nothing in this Agreement, and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or
communication from the Company limits the Service Provider’s ability to file a charge or complaint with any government agency concerning any acts or omissions that the Service Provider may believe constitute a possible violation of federal or
state law or making other disclosures that are protected under the whistleblower provisions of applicable U.S. federal or state law regulation or affects the Service Provider’s ability to communicate with any government agency or otherwise
participate in any investigation or proceeding that may be conducted by a government agency, including by providing documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the U.S. Defend
Trade Secrets Act of 2016, the Service Provider shall not be held criminally or civilly liable under any U.S. or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a U.S. federal, state, or
local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or
other proceeding, if such filing is made under seal. 

  
 8 of 12 

 Mandate Agreement 

 

	8.5.	 Injunction 

The Service Provider agrees that it would be difficult to measure any damages caused to the Company that might result from any breach by the Service Provider
of its obligations set forth in this Section 8, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, subject to Section 8, the Service Provider agrees that if it breaches, or proposes to
breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage
to the Company. 
 8.6    Acknowledgement 

The Parties acknowledge and agree that references to the term Service Provider in this Section 8 shall be deemed to include Advisor with equal force and
effect. 
  
  

	9.	 Final Provisions 

Integration: This Agreement, including its exhibit, constitutes the entire agreement between the Parties with respect to the subject matter hereof and
supersedes all prior agreements between the Parties concerning such subject matter. 
 Survival: The provisions of this Agreement shall survive the
termination of this Agreement to the extent necessary to effectuate the terms contained herein. 
 Enforceability: If any portion or provision of
this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the
application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law. 
 Waiver: No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving
Party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed
a waiver of any subsequent breach. 

  
 9 of 12 

 Mandate Agreement 

 

 Notices: Any notices, requests, demands and other communications provided for by this Agreement shall
be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Service Provider at the last address the Service
Provider has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the General Counsel. 
 Amendments:
This Agreement may be amended or modified only by a written instrument signed by the Service Provider and the Company. 
 Counterparts: This
Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

Assignment and Transfer by the Company: The Company has the right to assign and/or transfer this Agreement to its affiliates, successors and assigns.
The Service Provider expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate to whom this Agreement may be transferred without the necessity that this Agreement be re-signed at the time of such transfer. 
 Applicable Law and Place of Jurisdiction: This Agreement and all
disputes between the Parties in connection with this Agreement shall be governed by the laws of Switzerland excluding its conflict of laws rules. The place of jurisdiction for all disputes arising out of or in connection with this Agreement,
including disputes concerning the conclusion, validity, amendment or termination of this Agreement, shall be the registered office of the Company. 

[signatures on the next page] 

  
 10 of 12 

 Mandate Agreement 

 

 Signatures 
  

 

			
	 CRISPR Therapeutics AG
  

27 December 2019
  
	  	 /s/ Samarth Kulkarni

 

	 Date
	  	 Samarth Kulkarni

		  	 CEO and member of the Board

 

	 Oriolus Consulting LLC

 
 27 December 2019

 
	  	 /s/ Rodger Novak

 

	 Date
	  	 Dr. Rodger Novak

		  	 Manager and quotaholder

  
 11 of 12 

 Mandate Agreement 

 

 Exhibit 1.1 

Advisor Confirmation 
 I hereby confirm that I am aware of
the Mandate Agreement by and between CRISPR Therapeutics AG and Oriolus Consulting LLC dated as of 27 December 2019 (the Agreement). Terms defined in this confirmation shall have the meaning ascribed to such terms in the Agreement. 

I hereby undertake to provide the Services and assume the functions as Chairman and President in accordance with the Agreement. 

I personally undertake to comply with all provisions of the Agreement, including, but not limited to, the prohibition of competition and solicitation and the
confidentiality undertaking set forth in section 8 of the Agreement and the applicable law and jurisdiction provision set forth in section 9 of the Agreement. 
  

			
	 27 December 2019

 
	  	
	 Date
	  	 Dr. Rodger Novak

  
 12 of 12EX-10.2

 Exhibit 10.2 
  

 
 Termination Agreement 

dated as of 27 December 2019 
 by and between 

 
  

			
	CRISPR Therapeutics AG	  	(the Company)
	 Baarerstrasse 14, 6300 Zug, Switzerland

 
 and

 
	  	

  

 

			
	Rodger Novak	  	(Novak)
	 Husenstrasse 11, 6354 Vitznau, Switzerland
	  	

 (The Company and Novak are also referred to as Party or
Parties) 
 regarding 
  

 
 Termination of Employment Agreement 

 Termination Agreement 

 

  

Preamble 
  

	A.	 Novak’s employment relationship with the Company (the Employment Relationship) started on or about
1 November 2013. Novak transitioned from his position as the Chief Executive Officer of the Company to President of the Company effective as of 1 December 2017. 

 

	B.	 The Company and Novak entered into a written employment agreement dated as of 6 October 2016, replaced by
a new employment agreement dated as of 1 December 2017 (the Employment Agreement). 

  

	C.	 The Employment Relationship and the Employment Agreement are governed by Swiss law. 

 

	D.	 The Parties propose that Novak provide services to the Company as its chairman of the board of directors and as
its president (the Services). The Services do not constitute an employment relationship within the meaning of articles 319 et seq. of the Swiss Code of Obligations. 

 

	E.	 Consequently, the Parties agree to terminate the Employment Agreement (except as otherwise provided herein) and
the Employment Relationship governed by it. Henceforth, Novak intends to provide the Services based on a mandate agreement, to be entered into as of the date hereof by and between a company owned by Novak and the Company (the Mandate
Agreement). 

 Therefore, the Parties enter into the following termination agreement (the Agreement): 

 
  

	1.	 Termination of Employment Relationship 

Notwithstanding anything to the contrary set forth in the Employment Agreement, the Parties agree to terminate and hereby terminate the
Employment Agreement (except as otherwise provided herein) and the Employment Relationship governed by it with effect as of 1 January 2020 (the Termination Date) without the requirement or necessity of providing notice or any
renumeration in connection therewith. Any extension of the Employment Relationship, including due to illness, shall be expressly excluded. 

 Termination Agreement 

 

  

	2.	 Consequences of Termination 

 

	2.1.	 Performance of Work 

Until the Termination Date Novak will perform his normal duties under the Employment Agreement, as the Company may from time to time reasonably
request. 
  

	2.2.	 Remuneration 

  

	2.2.1.	 Salary 

From the signing of this Agreement until the Termination Date, the Company will continue to pay to Novak the same base salary as before. 

 

	2.2.2.	 Stock Options 

With respect to the equity awards granted by the Company and held by Novak that are outstanding and unvested as of the Termination Date
pursuant to the Employment Agreement, the vesting shall not be affected by this Agreement such that the outstanding equity awards continue to vest in accordance with the Employment Agreement. 

In furtherance of the foregoing, the last two sentences of Section 4(g) of the Employment Agreement, Section 7 of the Employment
Agreement as well as any related provisions of the Employment Agreement regarding the accelerated vesting of stock options in case of a Change in Control (as such term is defined in the Employment Agreement) shall, in each case, continue to remain
in full force mutatis mutandis, it being understood, that, for the purpose of clarification, (i) the Parties acknowledge, agree and intend that, notwithstanding anything to the contrary in the Employment Agreement, Novak will continue
vesting in the stock options described in Section 4(g) of the Employment Agreement for as long as he provides services as the president of the Company or such other officer position as is approved by the Company’s Board of Directors and
(ii) the date of termination of the Employment Agreement shall be the termination date of the Mandate Agreement. 

 Termination Agreement 

 

	2.2.3.	 Deductions 

The same social security deductions as in the past will be made from all payments under this Agreement. 

 
  

	3.	 Acknowledgement, Release and Waiver 

Upon execution and performance of this Termination Agreement neither Party shall have any further rights or claims against the other Party in
connection with the Employment Agreement and the Employment Relationship governed by it and its termination, except for the entitlements expressly mentioned in this Agreement. 

 
  

	4.	 Miscellaneous 

 

	4.1.	 Integration 

This Agreement and the Mandate Agreement, including their respective exhibits, constitute the entire agreement between the Parties with respect
to the subject matter hereof and thereof and supersede all prior agreements between the Parties concerning such subject matter. 
  

	4.2.	 Survival 

The provisions of this Agreement shall survive the termination of this Agreement to the extent necessary to effectuate the terms contained
herein. 
  

	4.3.	 Enforceability 

If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall
to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or
unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

 Termination Agreement 

 

	4.4.	 Waiver 

No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving Party. The failure of any party to
require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

  

	4.5.	 Notices 

Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in
person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to Novak at the last address Novak has filed in writing with the Company or, in the case of the
Company, at its main offices, attention of the General Counsel. 
  

	4.6.	 Amendments 

This Agreement may be amended or modified only by a written instrument signed by Novak and the Company. 

 

	4.7.	 Counterparts 

This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original;
but such counterparts shall together constitute one and the same document. 
  

	4.8.	 Assignment and Transfer by the Company 

The Company has the right to assign and/or transfer this Agreement to its affiliates, successors and assigns. Novak expressly consents to be
bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate to whom this Agreement may be transferred without the necessity that this Agreement be re-signed at the
time of such transfer. 

 Termination Agreement 

 

	4.9.	 Applicable Law and Place of Jurisdiction 

This Agreement and all disputes between the Parties in connection with this Agreement shall be governed by the laws of Switzerland excluding
its conflict of laws rules. Any dispute, controversy or claim arising out of or in connection with this Agreement shall be determined by the courts at the domicile of the defendant party or where Novak normally had to perform his duties. 

[signatures on the next page] 

 Termination Agreement 

 

  

			
	 Signatures
  
	  	
	 CRISPR Therapeutics AG

 
	  	 Company
  

	27 December 2019	  	/s/ Samarth Kulkarni
	 Date
  
	  	 Samarth Kulkarni
  

	 	  	 Novak
  

	27 December 2019	  	/s/ Rodger Novak
	Date	  	Rodger Novak

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]